In part 4 of this Exclusive Interview, Todd Hobbs talks with Diabetes in Control Publisher Steve Freed about the benefits of both an SGLT-2 and GLP-1 injectable, as found in the Dual 9 study.

In part 5 of this Exclusive Interview, Todd Hobbs talks with Diabetes in Control Publisher Steve Freed about the overall results of the Confirm real-world study.

In part 6, the conclusion of this Exclusive Interview, Todd Hobbs talks with Diabetes in Control Publisher Steve Freed about the upcoming focus on treating obesity as well as an oral form of semaglutide.

Higher risks seen for obesity, type 2 diabetes, circulatory system diseases

Excess hospitalizations seen across life span with large burden of mental illness in young adulthood